AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets

Simply Wall St.01-30 16:38

AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. ABCL635 is a non hormonal candidate for treating moderate to severe ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2607604810?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276","is_english":true,"pubTime":"2026-01-30 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607604810","market":"nz","top_or_hot":-1,"title":"AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets","media":"Simply Wall St.","content":"<div>\n<p>AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. ABCL635 is a non hormonal candidate for treating moderate to severe ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbCellera Advances ABCL635 Menopause Candidate As Shares Trade Below Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-30 16:38 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. ABCL635 is a non hormonal candidate for treating moderate to severe ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra","article_id":"2607604810","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice2-main-header/1585186774276"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/abcellera-advances-abcl635-menopause-candidate-as-shares-tra","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2607604810","pubTimestamp":1769762283,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635.\nABCL635 is a non hormonal candidate for treating moderate to severe vasomotor symptoms associated with menopause.\nThis Phase 2 dosing milestone marks further clinical progress in the company's efforts to develop a potential first in class menopause therapy.\n\nAbCellera Biologics, known for its antibody discovery platform, is pushing deeper into clinical development...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4535":"淡马锡持仓","ABCL":"AbCellera Biologics","BK4121":"生命科学工具和服务"},"translate_title":"由于股价低于目标，AbCellera推进ABCL635更年期候选药物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":0.9},"content_text":"AbCellera Biologics (NasdaqGS:ABCL) has begun dosing patients in the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635. ABCL635 is a non hormonal candidate for treating moderate to severe vasomotor symptoms associated with menopause. This Phase 2 dosing milestone marks further clinical progress in the company's efforts to develop a potential first in class menopause therapy.  AbCellera Biologics, known for its antibody discovery platform, is pushing deeper into clinical development with ABCL635 as part of its broader pipeline. Menopause related vasomotor symptoms such as hot flashes and night sweats remain an area where many patients seek non hormonal options, so any progress in this category tends to draw interest from both healthcare providers and investors. For NasdaqGS:ABCL, moving into Phase 2 with ABCL635 highlights how the company is transitioning from pure discovery toward later stage programs. For you as an investor, this kind of clinical milestone often raises questions around future data readouts, regulatory paths, and potential partnership interest. While outcomes are uncertain, Phase 2 initiation typically means safety data from earlier dosing were sufficient to justify a larger patient group, which can set the stage for more decision relevant efficacy data over time. Stay updated on the most important news stories for AbCellera Biologics by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on AbCellera Biologics. NasdaqGS:ABCL Earnings & Revenue Growth as at Jan 2026 How AbCellera Biologics stacks up against its biggest competitors AdvertisementQuick Assessment  ✅ Price vs Analyst Target: At US$3.86, the share price sits about 60.7% below the US$9.83 analyst target range midpoint. ✅ Simply Wall St Valuation: Shares are described as trading 77.4% below the platform's estimated fair value. ✅ Recent Momentum: The stock has returned 11.9% over the last 30 days.  Check out Simply Wall St's\nin-depth valuation analysis for AbCellera Biologics. Key Considerations  📊 Phase 2 dosing for ABCL635 moves the menopause program further along the clinic, which can be important for how you think about the pipeline story. 📊 Keep an eye on upcoming trial updates, cash burn, and whether ABCL635 attracts partners or additional funding interest. ⚠️ Clinical development carries binary outcomes, so negative efficacy or safety data from this trial could weigh on sentiment and future funding options.  Dig Deeper For the full picture including more risks and rewards, check out the\ncomplete AbCellera Biologics analysis.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2607604810","isCrawlerRequest":true}